Galectin Therapeutics (GALT) Proxy Filing summary

Executive summary

• Annual meeting scheduled for December 3, 2025, with virtual participation available to shareholders.

• Shareholders are encouraged to review proxy materials and vote by December 2, 2025.

Voting matters and shareholder proposals

• Election of eleven directors is up for shareholder vote.

• Advisory vote on executive compensation for named executive officers.

• Advisory vote on the frequency of future executive compensation votes.

• Ratification of Cherry Bekaert LLP as independent auditor for fiscal year ending December 31, 2025.

• Provision to transact other business as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends all nominated directors for election.

• Director nominees include individuals with diverse backgrounds in science, medicine, and business.